Novartis’ phase III MS study successfully meets endpoints
Novartis’ phase III study, evaluating the efficacy and safety of BAF312 (siponimod) in secondary progressive multiple sclerosis (SPMS), successfully met its primary endpoint of a reduction in the risk of disability progression, compared with placebo.
Click on this link for more information.
